AG˹ٷ

STOCK TITAN

[Form 4] Quince Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quince Therapeutics (QNCX) filed a Form 4 disclosing that CEO, CMO and Director Dirk Thye increased his equity stake on 18 June 2025.

Thye acquired 150,944 common shares at $1.20 (Transaction Code A) and simultaneously received warrants for an additional 150,944 shares with the same $1.20 exercise price, expiring 18 June 2030. Following the transactions, his direct beneficial ownership rose to 994,885 common shares, an increase of roughly 15 %. The disclosed cash outlay for the common-share purchase is approximately $181 000; the warrants were priced at $0.125 each.

No shares were sold, and the filing does not indicate the use of a Rule 10b5-1 trading plan. These insider purchases may signal management confidence, though the dollar value is modest relative to typical market-moving thresholds.

Quince Therapeutics (QNCX) ha presentato un Modulo 4 rivelando che l'Amministratore Delegato, Direttore Medico e Direttore Dirk Thye ha aumentato la sua partecipazione azionaria il 18 giugno 2025.

Thye ha acquisito 150.944 azioni ordinarie a $1,20 (Codice Transazione A) e contemporaneamente ha ricevuto warrant per ulteriori 150.944 azioni con lo stesso prezzo di esercizio di $1,20, con scadenza il 18 giugno 2030. Dopo queste operazioni, la sua proprietà diretta è salita a 994.885 azioni ordinarie, un aumento di circa il 15%. La spesa in contanti dichiarata per l'acquisto delle azioni ordinarie è di circa $181.000; i warrant sono stati valutati a $0,125 ciascuno.

Non sono state vendute azioni e il documento non indica l'uso di un piano di trading Rule 10b5-1. Questi acquisti da parte di un insider possono indicare fiducia da parte del management, anche se il valore in dollari è modesto rispetto alle soglie tipiche che muovono il mercato.

Quince Therapeutics (QNCX) presentó un Formulario 4 revelando que el CEO, CMO y Director Dirk Thye incrementó su participación accionaria el 18 de junio de 2025.

Thye adquirió 150,944 acciones comunes a $1.20 (Código de Transacción A) y simultáneamente recibió warrants por otras 150,944 acciones con el mismo precio de ejercicio de $1.20, que vencen el 18 de junio de 2030. Tras estas transacciones, su propiedad directa aumentó a 994,885 acciones comunes, un incremento de aproximadamente el 15%. El desembolso en efectivo declarado para la compra de acciones comunes fue de aproximadamente $181,000; los warrants se valoraron en $0.125 cada uno.

No se vendieron acciones y el informe no indica el uso de un plan de negociación Rule 10b5-1. Estas compras por parte de un insider pueden señalar confianza en la gestión, aunque el valor en dólares es modesto en comparación con los umbrales típicos que mueven el mercado.

Quince Therapeutics (QNCX)� CEO, CMO � 이사� Dirk Thye2025� 6� 18�� 지분을 늘렸음을 공개하는 Form 4� 제출했습니다.

ճ� 150,944 보통주를 주당 $1.20� 매수하였으며(거래 코드 A), 동시� 동일� 행사갶� $1.20, 만기� 2030� 6� 18일인 추갶� 150,944 주에 대� 워런�� 받았습니�. � 거래 이후 그의 직접 보유 지분은 994,885 보통�� � 15% 증갶했습니�. 보통� 매입� 대� 현금 지출은 � $181,000이며, 워런트는 각각 $0.125� 평갶되었습니다.

주식 매도� 없었�, 제출 서류에는 Rule 10b5-1 거래 계획 사용 여부갶 명시되어 있지 않습니다. 이러� 내부� 매입은 경영진의 신뢰� 나타� � 있으�, 금액은 시장� � 영향� 미치� 일반적인 기준� 비해 비교� 적은 편입니다.

Quince Therapeutics (QNCX) a déposé un formulaire 4 révélant que le PDG, CMO et administrateur Dirk Thye a augmenté sa participation en actions le 18 juin 2025.

Thye a acquis 150 944 actions ordinaires à 1,20 $ (Code de transaction A) et a simultanément reçu des warrants pour 150 944 actions supplémentaires au même prix d'exercice de 1,20 $, expirant le 18 juin 2030. Après ces transactions, sa détention directe est passée à 994 885 actions ordinaires, soit une augmentation d'environ 15 %. La dépense en espèces déclarée pour l'achat des actions ordinaires est d'environ 181 000 $ ; les warrants ont été valorisés à 0,125 $ chacun.

Aucune action n'a été vendue et le dépôt ne mentionne pas l'utilisation d'un plan de trading Rule 10b5-1. Ces achats d'initiés peuvent indiquer la confiance de la direction, bien que la valeur en dollars soit modeste par rapport aux seuils habituels ayant un impact significatif sur le marché.

Quince Therapeutics (QNCX) hat ein Formular 4 eingereicht, das offenlegt, dass CEO, CMO und Direktor Dirk Thye am 18. Juni 2025 seinen Aktienanteil erhöht hat.

Thye erwarb 150.944 Stammaktien zu je 1,20 $ (Transaktionscode A) und erhielt gleichzeitig Warrants für weitere 150.944 Aktien mit demselben Ausübungspreis von 1,20 $, die am 18. Juni 2030 verfallen. Nach diesen Transaktionen stieg sein direkter Eigentumsanteil auf 994.885 Stammaktien, eine Steigerung von etwa 15 %. Der ausgewiesene Baraufwand für den Kauf der Stammaktien beträgt etwa 181.000 $; die Warrants wurden mit jeweils 0,125 $ bewertet.

Es wurden keine Aktien verkauft, und in der Meldung wird die Nutzung eines Rule 10b5-1 Handelsplans nicht angegeben. Diese Insider-Käufe könnten auf Vertrauen des Managements hinweisen, obwohl der Dollarbetrag im Vergleich zu üblichen marktrelevanten Schwellenwerten eher gering ist.

Positive
  • CEO insider purchase: Dirk Thye acquired 150,944 common shares at $1.20, increasing his direct stake by roughly 15 %.
  • Long-dated warrants: He also obtained warrants for 150,944 shares exercisable at $1.20 until 18 June 2030, underscoring long-term commitment.
Negative
  • None.

Insights

TL;DR: CEO adds 15 % to holding; positive signal but limited monetary size.

The Form 4 shows Dirk Thye buying 150,944 shares plus identical warrants at $1.20. While the purchase value (~$181k) is small versus Quince’s likely market cap and liquidity, the 15 % boost to the CEO’s direct stake and the five-year warrants align his interests more closely with shareholders. Absence of any sales removes overhang fears. Historically, insider buying at market price is a bullish indicator, yet the size suggests only incremental impact. Overall, directionally positive but not a game-changer.

Quince Therapeutics (QNCX) ha presentato un Modulo 4 rivelando che l'Amministratore Delegato, Direttore Medico e Direttore Dirk Thye ha aumentato la sua partecipazione azionaria il 18 giugno 2025.

Thye ha acquisito 150.944 azioni ordinarie a $1,20 (Codice Transazione A) e contemporaneamente ha ricevuto warrant per ulteriori 150.944 azioni con lo stesso prezzo di esercizio di $1,20, con scadenza il 18 giugno 2030. Dopo queste operazioni, la sua proprietà diretta è salita a 994.885 azioni ordinarie, un aumento di circa il 15%. La spesa in contanti dichiarata per l'acquisto delle azioni ordinarie è di circa $181.000; i warrant sono stati valutati a $0,125 ciascuno.

Non sono state vendute azioni e il documento non indica l'uso di un piano di trading Rule 10b5-1. Questi acquisti da parte di un insider possono indicare fiducia da parte del management, anche se il valore in dollari è modesto rispetto alle soglie tipiche che muovono il mercato.

Quince Therapeutics (QNCX) presentó un Formulario 4 revelando que el CEO, CMO y Director Dirk Thye incrementó su participación accionaria el 18 de junio de 2025.

Thye adquirió 150,944 acciones comunes a $1.20 (Código de Transacción A) y simultáneamente recibió warrants por otras 150,944 acciones con el mismo precio de ejercicio de $1.20, que vencen el 18 de junio de 2030. Tras estas transacciones, su propiedad directa aumentó a 994,885 acciones comunes, un incremento de aproximadamente el 15%. El desembolso en efectivo declarado para la compra de acciones comunes fue de aproximadamente $181,000; los warrants se valoraron en $0.125 cada uno.

No se vendieron acciones y el informe no indica el uso de un plan de negociación Rule 10b5-1. Estas compras por parte de un insider pueden señalar confianza en la gestión, aunque el valor en dólares es modesto en comparación con los umbrales típicos que mueven el mercado.

Quince Therapeutics (QNCX)� CEO, CMO � 이사� Dirk Thye2025� 6� 18�� 지분을 늘렸음을 공개하는 Form 4� 제출했습니다.

ճ� 150,944 보통주를 주당 $1.20� 매수하였으며(거래 코드 A), 동시� 동일� 행사갶� $1.20, 만기� 2030� 6� 18일인 추갶� 150,944 주에 대� 워런�� 받았습니�. � 거래 이후 그의 직접 보유 지분은 994,885 보통�� � 15% 증갶했습니�. 보통� 매입� 대� 현금 지출은 � $181,000이며, 워런트는 각각 $0.125� 평갶되었습니다.

주식 매도� 없었�, 제출 서류에는 Rule 10b5-1 거래 계획 사용 여부갶 명시되어 있지 않습니다. 이러� 내부� 매입은 경영진의 신뢰� 나타� � 있으�, 금액은 시장� � 영향� 미치� 일반적인 기준� 비해 비교� 적은 편입니다.

Quince Therapeutics (QNCX) a déposé un formulaire 4 révélant que le PDG, CMO et administrateur Dirk Thye a augmenté sa participation en actions le 18 juin 2025.

Thye a acquis 150 944 actions ordinaires à 1,20 $ (Code de transaction A) et a simultanément reçu des warrants pour 150 944 actions supplémentaires au même prix d'exercice de 1,20 $, expirant le 18 juin 2030. Après ces transactions, sa détention directe est passée à 994 885 actions ordinaires, soit une augmentation d'environ 15 %. La dépense en espèces déclarée pour l'achat des actions ordinaires est d'environ 181 000 $ ; les warrants ont été valorisés à 0,125 $ chacun.

Aucune action n'a été vendue et le dépôt ne mentionne pas l'utilisation d'un plan de trading Rule 10b5-1. Ces achats d'initiés peuvent indiquer la confiance de la direction, bien que la valeur en dollars soit modeste par rapport aux seuils habituels ayant un impact significatif sur le marché.

Quince Therapeutics (QNCX) hat ein Formular 4 eingereicht, das offenlegt, dass CEO, CMO und Direktor Dirk Thye am 18. Juni 2025 seinen Aktienanteil erhöht hat.

Thye erwarb 150.944 Stammaktien zu je 1,20 $ (Transaktionscode A) und erhielt gleichzeitig Warrants für weitere 150.944 Aktien mit demselben Ausübungspreis von 1,20 $, die am 18. Juni 2030 verfallen. Nach diesen Transaktionen stieg sein direkter Eigentumsanteil auf 994.885 Stammaktien, eine Steigerung von etwa 15 %. Der ausgewiesene Baraufwand für den Kauf der Stammaktien beträgt etwa 181.000 $; die Warrants wurden mit jeweils 0,125 $ bewertet.

Es wurden keine Aktien verkauft, und in der Meldung wird die Nutzung eines Rule 10b5-1 Handelsplans nicht angegeben. Diese Insider-Käufe könnten auf Vertrauen des Managements hinweisen, obwohl der Dollarbetrag im Vergleich zu üblichen marktrelevanten Schwellenwerten eher gering ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thye Dirk

(Last) (First) (Middle)
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD., SUITE 273

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and CMO
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/18/2025 A 150,944 A $1.2 994,885 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $1.2 06/18/2025 A 150,944 06/18/2025 06/18/2030 Common Shares 150,944 $0.125 150,944 D
Explanation of Responses:
/s/ Dirk Thye 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many QNCX shares did CEO Dirk Thye purchase on 18 June 2025?

He bought 150,944 common shares according to the Form 4.

What price did Dirk Thye pay for the newly acquired QNCX shares?

The filing lists a purchase price of $1.20 per share.

What is Dirk Thye’s total direct ownership in QNCX after the transaction?

Following the acquisition, Thye directly owns 994,885 common shares.

Did the QNCX CEO acquire any derivative securities?

Yes. He received warrants for 150,944 shares with a $1.20 exercise price expiring on 18 June 2030.

Was the trade executed under a Rule 10b5-1 trading plan?

The Form 4 includes a checkbox for Rule 10b5-1 trades, but it is not marked; no such plan is indicated.
Quince

NASDAQ:QNCX

QNCX Rankings

QNCX Latest News

QNCX Latest SEC Filings

QNCX Stock Data

83.43M
39.50M
13.52%
23.46%
5.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO